EUVIMEDEUVIMED entdecken
Crossref

The Effect of PCSK9 Monoclonal Antibodies on Platelet Reactivity and Cardiovascular Events in Patients Receiving Primary Percutaneous Coronary Intervention: A Propensity Score-Matched Analysis

Yao Yao, Qining Qiu, Zi Wang, Shikun Xu, Qianzhou Lv

American Journal of Cardiovascular Drugs · 2025-07 · 25 (4) · 519-532

DOI: 10.1007/s40256-024-00719-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Cardiovascular Drugs, online erschienen am 15.01.2025. Verfasst von Yao Yao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Blood Platelets, Acute Coronary Syndrome. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) have demonstrated promising effects in lowering cardiovascular incidents among patients with acute coronary syndrome. However, their influence on early platelet reactivity after primary percutaneous coronary intervention (PPCI) remains unclear. OBJECTIVES: This research sought to investigate the effects of entirely human anti-PCSK9 antibodies on platelet function as measured by thrombelastography and 12-month postoperative results in patients receiving PPCI and treated with ticagrelor-based dual antiplatelet therapy. METHODS: This single-center prospective study was conducted at Zhongshan Hospital, Fudan University, China, between January 2021 and June 2023. Patients were divided into two groups: those receiving standard statin therapy (statin-only group) and those receiving additional PCSK9 mAbs (either evolocumab 140 mg or alirocumab 75 mg, subcutaneously, every 2 weeks; PCSK9 mAb group). A total of 1250 eligible patients were enrolled. To equalize baseline characteristics, propensity score matching was conducted in a 1:1 ratio, resulting in 310 patients per group. Platelet activity was measured using thrombelastography 5 days after PPCI, presented as adenosine diphosphate-induced maximal amplitude (MAADP). The primary clinical outcome was the occurrence of major adverse cardiovascular events, which included cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, and coronary revascularization, measured over a 12-month period. RESULTS: At 5 days after PPCI, the PCSK9 mAb group exhibited levels of MAADP that were significantly lower than those in the statin-only group (17.10 ± 9.52 mm vs. 20.73 ± 12.07 mm, P 21.7 mm) plus statin-only subgroup exhibited the lowest rate of cumulative event-free survival. CONCLUSION: Incorporating PCSK9 mAbs into ticagrelor-based dual antiplatelet therapy significantly reduced platelet reactivity and correlated with better cardiovascular results over a 12-month period. These findings support the use of PCSK9 mAbs as an effective adjunctive therapy in the management of acute coronary syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionPlatelet Aggregation InhibitorsBlood PlateletsAcute Coronary SyndromeAntibodies, MonoclonalPCSK9 InhibitorsHumansMaleFemaleMiddle AgedProspective StudiesAgedPropensity ScoreProprotein Convertase 9TicagrelorAntibodies, Monoclonal, HumanizedHydroxymethylglutaryl-CoA Reductase InhibitorsDrug Therapy, Combination

Substanzen

PCSK9 protein, humanPlatelet Aggregation InhibitorsevolocumabProprotein Convertase 9alirocumabTicagrelorAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Pharmacy, Zhongshan Hospital, Fudan University, Xiamen, Fujian, China.
  • Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China. xu.shikun@zs-hospital.sh.cn.
  • Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China. 13916088938@163.com.

Zitieren

APA

Yao, Y., Qiu, Q., Wang, Z., Xu, S., & Lv, Q. (2025). The Effect of PCSK9 Monoclonal Antibodies on Platelet Reactivity and Cardiovascular Events in Patients Receiving Primary Percutaneous Coronary Intervention: A Propensity Score-Matched Analysis. American Journal of Cardiovascular Drugs, 25(4), 519-532. https://doi.org/10.1007/s40256-024-00719-4

Vancouver

Yao Y, Qiu Q, Wang Z, Xu S, Lv Q. The Effect of PCSK9 Monoclonal Antibodies on Platelet Reactivity and Cardiovascular Events in Patients Receiving Primary Percutaneous Coronary Intervention: A Propensity Score-Matched Analysis. American Journal of Cardiovascular Drugs. 2025;25(4):519-532. doi:10.1007/s40256-024-00719-4

BibTeX
@article{Yao2025,
  author = {Yao, Yao and Qiu, Qining and Wang, Zi and Xu, Shikun and Lv, Qianzhou},
  title = {The Effect of PCSK9 Monoclonal Antibodies on Platelet Reactivity and Cardiovascular Events in Patients Receiving Primary Percutaneous Coronary Intervention: A Propensity Score-Matched Analysis},
  journal = {American Journal of Cardiovascular Drugs},
  year = {2025},
  volume = {25},
  number = {4},
  pages = {519--532},
  doi = {10.1007/s40256-024-00719-4}
}
Kostenlos starten →